Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays

Thrombosis and Haemostasis

Volumn 105, Issue 2, 2011, Pages 371-378

  Lindahl, Tomas L ^a   Baghaei, Fariba ^b   Blixter, Inger Fagerberg ^c   Gustafsson, Kerstin M ^a   Stigendal, Lennart ^b   Sten Linder, Margareta ^d   Strandberg, Karin ^e   Hillarp, Andreas ^e  

^a LINKÖPING UNIVERSITY   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

^e Clinical Microbiology Regional and University Laboratories   (Sweden)

Author keywords

Anticoagulant; Coagulation assays; Dabigatran; Interference; Thrombin inhibitor

Indexed keywords

ANTITHROMBIN; DABIGATRAN; FIBRINOGEN; REAGENT;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ARTICLE; ASSAY; BLOOD CLOTTING TEST; CONCENTRATION RESPONSE; DILUTION; DRUG EFFECT; FEMALE; HUMAN; MALE; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PLASMA; PRIORITY JOURNAL; PROTHROMBIN TIME;

ACTIVATED PROTEIN C RESISTANCE; ADMINISTRATION, ORAL; ADULT; AGED; ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; BLOOD COAGULATION; BLOOD COAGULATION TESTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBRINOGEN; HUMANS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; REPRODUCIBILITY OF RESULTS; THROMBIN;

EID: 79851482951     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-06-0342     Document Type: Article

References (26)

1. Rost S, Fregin A, Ivaskevicius V, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004; 42: 537-541. (Pubitemid 38209110)
2. Osman A, Enstrom C, Arbring K, et al. Main haplotypes and mutational analysis of vitamin K epoxide reductase (VKORC1) in a Swedish population: a retrospective analysis of case records. J Thromb Haemost 2006; 4: 1723-1729. (Pubitemid 44144799)
3. Schulman S, Wahlander K, Lundstrom T, et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003; 349: 1713-1721. (Pubitemid 37315008)
4. Eriksson BI, Bergqvist D, Kalebo P, et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002; 360: 1441-1447. (Pubitemid 35356320)
5. Agnelli G, Eriksson BI, Cohen AT, et al. Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran. Thromb Res 2009; 123: 488-497.
6. Mattsson C, Menschiek-Lundin A, Wahlander K, et al. Effect of melagatran on prothrombin time assays depends on the sensitivity of the thromboplastin and the final dilution of the plasma sample. Thromb Haemost 2001; 86: 611-615. (Pubitemid 32743274)
7. Harder S, Graff J, Klinkhardt U, et al. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time. Thromb Haemost 2004; 91: 1137-1145. (Pubitemid 38821270)
8. Walenga JM, Drenth AF, Mayuga M, et al. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effect on coagulation factor testing. Clin Appl Thromb Hemost 2008; 14: 325-331. (Pubitemid 351871948)
9. Fenyvesi T, Joerg I, Harenberg J. Influence of lepirudin, argatroban, and melagatran on prothrombin time and additional effect of oral anticoagulation. Clin Chem 2002; 48: 1791-1794.
10. Siegmund R, Boer K, Poeschel K, et al. Influence of direct thrombin inhibitor argatroban on coagulation assays in healthy individuals, patients under oral anticoagulation therapy and patients with liver dysfunction. Blood Coagul Fibrinolysis 2008; 19: 288-293. (Pubitemid 351670413)
11. Fenyvesi T, Jorg I, Weiss C, et al. Effects of lepirudin, argatroban and melagatran and additional influence of phenprocoumon on ecarin clotting time. Thromb Res 2003; 111: 89-94. (Pubitemid 37485931)
12. Hursting MJ, Zehnder JL, Joffrion JL, et al. The International Normalized Ratio during concurrent warfarin and argatroban anticoagulation: differential contributions of each agent and effects of the choice of thromboplastin used. Clin Chem 1999; 45: 409-412. (Pubitemid 29114179)
13. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949-956. (Pubitemid 47393577)
14. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5: 2178-2185. (Pubitemid 47617868)
15. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
16. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-2352.
17. Stangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005; 45: 555-563. (Pubitemid 40562946)
18. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008; 47: 285-295. (Pubitemid 351508116)
19. Lindahl TL, Egberg N, Hillarp A, et al. INR calibration of Owren-type prothrombin time based on the relationship between PT% and INR utilizing normal plasma samples. Thromb Haemost 2004; 91: 1223-1231. (Pubitemid 38821281)
20. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-1127.
21. Stangier J, Stahle H, Rathgen K, et al. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008; 47: 47-59. (Pubitemid 350260888)
22. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-1127.
23. Blech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008; 36: 386-399. (Pubitemid 351185753)
24. Stangier J, Rathgen K, Stahle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64: 292-303. (Pubitemid 47283865)
25. Stangier J, Rathgen K, Stahle H, et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010; 49: 259-268.
26. Molinaro RJ, Szlam F, Levy JH, et al. Low plasma fibrinogen levels with the Clauss method during anticoagulation with bivalirudin. Anesthesiology 2008; 109: 160-161.